tbuckley/cabot-search huggingface dataset:
Cardiothoracic Surgery
Authors: Thomas W. Shields
Journal: JAMA (1984)

There has been a resurgence of interest in the use of the internal mammary artery for coronary bypass grafting.<sup>1-3</sup>An average patency rate of 94.1% at 60 to 100 months following internal mammary artery grafting of the left anterior descending artery has been reported.<sup>4</sup>Difficulties with anastomosis and pedicle injury during preparation can be reduced to 2% or less by introducing magnification and microsurgical technique. Emergency revascularization of the early acute myocardial infarct continues to receive much attention. In a ten-year follow-up study, the Spokane group reported a 5.2% early mortality rate and a 12% late mortality rate when revascularization was performed in patients with transmural myocardial infarcts that were less than 24 hours old.<sup>5</sup>Similar results have been obtained for nontransmural myocardial infarcts. In a three-armed study comparing intracoronary streptokinase, percutaneous transluminal angioplasty, and emergency coronary artery bypass grafting, a combined approach to managing the acute
Evaluation of 11 Commercially Available Rapid Influenza Diagnostic Tests—United States, 2011-2012
Journal: JAMA (2013)

Accurate diagnosis of influenza is critical for clinical management, infection control, and public health actions to minimize the burden of disease. Commercially available rapid influenza diagnostic tests (RIDTs) that detect the influenza virus nucleoprotein (NP) antigen are widely used in clinical practice for diagnosing influenza because they are simple to use and provide results within 15 minutes; however, there has not been a recent comprehensive analytical evaluation of available RIDTs using a standard method with a panel of representative seasonal influenza viruses. This report describes an evaluation of 11 Food and Drug Administration (FDA)-cleared RIDTs using 23 recently circulating influenza viruses under identical conditions in a laboratory setting to assess analytical performance. Most RIDTs detected viral antigens in samples with the highest influenza virus concentrations, but detection varied by virus type and subtype at lower concentrations. Clinicians should be aware of the variability of RIDTs when interpreting negative results and should collect test samples using methods that can maximize the concentration of virus antigen in the sample, such as collecting adequate specimens using appropriate methods in the first 24-72 hours after illness onset. The study design described in this report can be used to evaluate the performance of RIDTs available in the United States now and in the future.
HEMATOZOON INFECTION IN RATS.
Journal: JAMA (1900)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Lymphoma recurrence 5 years or more following diffuse large B-cell lymphoma: Clinical characteristics and outcome
Authors: J. Larouche, F. Berger, C. Chassagne-Clement, C. Sebban, H. Ghesquieres, G. Salles, B. Coiffier
Journal: Journal of Clinical Oncology (2009)

8562 Background: Diffuse large B-cell lymphoma (DLBCL) usually relapses early following treatment but some relapses happen 5 years or later. Few data exist regarding clinical characteristics and outcome of these patients (pts). Methods: We performed a retrospective analysis of all pts from two centers in Lyon/France between 1980–2003 who presented a biopsy proven relapse 5 years or later following diagnosis of DLBCL. All available biopsies were revised and immunohistochemistry (IHC) completed. Results: Among 1492 pts with DLBCL, 54 were eligible. Clinical characteristics at diagnosis were: median age 57 y; stage I-II 63% (34/54); IPI low/low intermediate 84% (41/49) and extranodal involvement (EN) 66% (35/53). IHC at diagnosis: CD20 100% (46/46), CD10 28% (10/36), bcl-6 53% (9/17), MUM1 48% (11/23), bcl-2 68% (19/28), germinal-center phenotype (GC) 57% (12/21) and non-GC 43% (9/21). 47/53 received CHOP/ACVBP-like regimens, 1 autologous transplantation (ASCT) and 1 rituximab. Median time from diagnosis to relapse was 7.4 years (5–20.5 years). 44 pts (81%) had DLBCL histology at time of relapse and 10 pts (19%) indolent histology. MUM1 expression at diagnosis was associated with DLBCL histology at relapse (p=0.037). Clinical characteristics at relapse were: median age 66 y; stage I-II 48% (26/54); 73% (31/43) with DLBCL at relapse had EN. 54% (15/28) with DLBCL at relapse had a GC phenotype and 46% (13/28) a non-GC phenotype. Treatment at relapse included rituximab in 21/54 and ASCT in 15/54 with 7 pts receiving both. Estimated 5-year event-free survival (EFS) and overall survival (OS) after relapse were 25% and 35% for all pts. Pts with DLBCL histology at relapse had an estimated 5-year EFS and OS of 18% and 28%. Pts with indolent histology had an estimated 5-year EFS and OS of 55% and 67%. Conclusions: Patients with DLBCL who present a late relapse usually had localized stage, favorable IPI and extranodal involvement at diagnosis. However, even if initial characteristics at time of first treatment were favorable, outcome of pts with DLBCL at time of relapse remains poor and aggressive treatment, such as ASCT, should be pursue whenever possible. Some patients relapsed with indolent histology and have a better outcome. No significant financial relationships to disclose.
The Plague.
Authors: W. F. Arnold
Journal: JAMA (1900)

New York, July 18, 1900. <h3>To the Editor:</h3> —May I presume to commend entirely your most timely and well considered article upon the plague situation in San Francisco? The infection with plague of San Francisco's Chinese quarter; the destruction by fire of such a shameful aggregation somewhere in American territory—and the consequent scattering of infective material broadcast—and the tedious and hampered efforts to control the infection, which can not be assured and can only succeed as the result of the most patient attention and inconceivable expense, were matters of confident prediction by me as long ago as the summer of 1896. The present justification of my then statements is not a matter for rejoicing: but I do take unusual pleasure in stating that the only persons who interested themselves in studying the bacillus of plague, which I brought to the United States with me then, were Dr. Douglas W. Montgomery,
Correction
Authors: B Mackenzie, Hegarty Marshall, Hector Smith, T Barras, F Mackenzie, J Keeling, J Simpson, C Sandford, J Forsyth, T Briggs, M Herford, L Fletcher, A Lieutenant-Colonel, C Eagger, W Lister, R Kelman, F Stammers, T Lieutenant-Colonels, T Samuel, W Blunt, W Mcintosh, C Cellan-Jones, T Murphy, A Harrison
Journal: BMJ (1953)

THEhospital consultants, as their advice, when sought, is usually studded with proprietary preparations.Very often, if the patient has been in hospital, he presents himself at the surgery with a detailed list of things he has to be given.We have yet to hear of a consultant having to justify his prescribing.Until such a time as the Minister has the courage to tackle the service as a whole-patients, consultants, G.P.s, chemists, and proprietary drug manufacturers-we consider he is un- likely to achieve the reduction in the drug bill we all wish to see.-We are, etc.,
Thrombolytic therapy in treatment: summary of an NIH Consensus Conference.
Journal: BMJ (1980)

A National Institutes of Health consensus development con- ference, held at NIH on 10-12 April 1980, addressed the issue of thrombolytic therapy for the management of acute deep-vein thrombosis and pulmonary embolism.The thrombolytic agents considered were urokinase and streptokinase.At NIH, consensus development conferences bring together biomedical research scientists, practising physicians, consumers, and others as appropriate in an effort to reach general agreement on the safety and effectiveness of a medical technology.That technology may be a drug, device, or medical or surgical procedure.A consensus development panel, after listening to expert presentations at the conference, issued the following consensus statement.For over three decades, the primary method of therapy used by almost all physicians for the management of acute deep-vein thrombosis and pulmonary embolism has been anticoagulation.This form of therapy has become so ingrained in medical practice that physicians, while still concerned over the bleeding risk associated with the use of anticoagulants, nevertheless seem secure in the belief that they are providing optimal, if not ideal, therapy for these disorders.With the advent of thrombolytic therapy, this is no longer true for a large number of cases.Anticoagulation for the management of acute deep-vein throm- bosis and pulmonary embolism, while usually effective in preventing or slowing further thrombus formation in veins and significantly diminishing the likelihood of subsequent or re- current embolisation, does not: * eliminate the source of subsequent embolisation in the deep veins during the acute attack; * alleviate the haemodynamic disturbances associated with the thrombosis or embolism; * prevent subsequent valvular damage to the deep veins and the development of persistent venous hypertension and associated symptoms in the lower extremities which may predispose to recurrent deep-vein thrombosis and pulmonary embolism;
Spot(s)
Authors: Bernard Robins
Journal: Annals of Internal Medicine (2005)

On Being a Doctor19 April 2005Spot(s)Bernard Robins, MDBernard Robins, MDFrom Lebanon, NJ 08833.Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-142-8-200504190-00019 SectionsAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail The telephone call came from the answering service at noon on a hot Wednesday in July of 1957. I had been in practice for about a month and was keeping busy making house calls for doctors on their days off or at night. This call was a request to visit a young man sick with a fever. I drove to the house, and I was met by a 15-year-old boy alone at home. His family was away for the day, and he didn't know how to reach them. He'd been well until early that same morning when he'd developed chills, ... Author, Article, and Disclosure InformationAffiliations: From Lebanon, NJ 08833.Corresponding Author: Bernard Robins, MD, 32 Hunters Circle, Lebanon, NJ 08833; e-mail, [email protected]net. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics 19 April 2005Volume 142, Issue 8Page: 675KeywordsAdolescentsFeversMemoryMotivationNauseaPenicillinRashesRunningSaline solutionsTemperature ePublished: 19 April 2005 Issue Published: 19 April 2005 Copyright & PermissionsCopyright © 2005 by American College of Physicians. All Rights Reserved.PDF downloadLoading ...
CIRCADIAN RHYTHMS
Journal: JAMA (1965)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Abstract 1658: Performance evaluation of assembly based structural variation discovery in paired tumor normal samples
Authors: Chunlin Xiao
Journal: Cancer Research (2019)

Abstract Structural variations (SVs) are well known to contribute to genetic diversity of human populations, affect biological functions, and cause various human disorders. However, accurately identifying SVs with correct sizes and locations in the human genome, particularly in cancer samples, remains a challenge due to the complexities of the human genome, limitations of sequencing technologies, and drawbacks of analysis methods. Recent advancement of next-generation sequencing technologies has significantly reduced the sequencing cost, while substantially increased the lengths of the sequencing reads. Therefore, using de novo assembly based approaches for discovering a full spectrum of SVs in human genome becomes tempting. While various assembly methods have been developed and proposed for general use by the community, the relative efficiency and predictive accuracy of SVs calling based on these assembly methods have not been fully evaluated. In this study, we applied several popular de novo assembly tools to the sequencing read data that were generated using multiple sequencing technologies with technical replicates for a paired tumor-normal samples. Assemblies and SVs callsets were generated, and repeatability in the SVs of the technical replicates and reproducibility across sequencing sites were evaluated. Results showed that there were substantial variabilities between SVs callsets based on various assemblies within sequencing platform and cross sequencing sites. We also observed considerable variabilities between assembly based SVs callsets and alignment based SVs callsets. The sources of these variabilities will be further discussed. These results allow better understanding of the impacts of de novo assembly methods on SVs calling, thus providing a better insight to precision medicine. Citation Format: Chunlin Xiao. Performance evaluation of assembly based structural variation discovery in paired tumor normal samples [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2019; 2019 Mar 29-Apr 3; Atlanta, GA. Philadelphia (PA): AACR; Cancer Res 2019;79(13 Suppl):Abstract nr 1658.
Protection by 16,16-dimethyl prostaglandin E2 and dibutyryl cyclic AMP against complement-mediated hepatic necrosis in rats
Authors: Y Kurebayashi
Journal: Hepatology (1991)

16,16-Dimethyl prostaglandin E2, a known cytoprotective agent, was examined for its ability to protect the liver against complement-mediated necrosis induced by an intravenous injection of a monoclonal antibody against a rat liver—specific antigen in rats. The hepatic injury induced by the antibody was characterized by (a) rapid development of numerous massive hemorrhagic foci of necrotic liver cells, (b) marked increases in serum liver enzyme activities and (c) pronounced reduction in the CH50 level, presumably as a result of complement consumption in the liver. Pretreatment with 16,16-dimethyl prostaglandin E2 at intraperitoneal doses of 20 and 100 μg/kg suppressed the hepatic injury, as evidenced by markedly mitigated liver-cell necrosis and much smaller increases in the serum-enzyme activities compared with the values in diseased control animals. The prostaglandin analogue failed to prevent serum complement consumption in response to the antibody injection or affect the CH50 level at the preinjury stage, indicating that neither complement inactivation nor interference with the antigen-antibody reaction was involved in the hepatic protection. The hepatoprotective doses of 16,16-dimethyl prostaglandin E2 produced a significant increase in liver cyclic AMP content in a dose-related manner. In addition, intravenous dibutyryl cyclic AMP at 3 and 10 mg/kg dose-dependently prevented histological and biochemical changes in the hepatic damage without altering the rate of reduction in serum complement activity. Like 16,16-dimethyl prostaglandin E2, dibutyryl cyclic AMP did not affect the preinjury CH50 level. These results suggest that increased hepatocellular cyclic AMP is responsible, at least in part, for the hepatic protection afforded by 16,16-dimethyl prostaglandin E2 against the membrane-damaging insult of activated complement, possibly through the stabilization of the plasma membrane.
Coronary Arteriography
Authors: Walt F. Weaver
Journal: JAMA (1976)

<h3>To the Editor.—</h3> We wish to thank Dr Manley for his editorial comments (235:846, 1976) referable to our study (235:819,1976) and for sharing his recent experience. We believe it is pertinent to answer the questions he posed regarding our report and have the following comments. As regards the "quality of angiography" referable to "whether any of the angiography had to be repeated at the institution where the coronary bypass surgery was performed," we wish to point out that we initiated a dual cardiac diagnostic<i>and surgical</i>program in 1965 and have reported our surgical experience.<sup>1</sup>Three hundred and four patients were studied from 1965 to July 1971. Methods of study including technical details (such as 16-mm filming methods) were so varied that we believed inclusion in the present study would be confusing to the reader. We also believed that it was justified statistically not to include this group since
Manuscripts Approved for JNCI, December 1, 1964, to January 1, 1965
Journal: JNCI Journal of the National Cancer Institute (1965)

Journal Article Manuscripts Approved for JNCI, December 1, 1964, to January 1, 1965 Get access JNCI: Journal of the National Cancer Institute, Volume 34, Issue 2, February 1965, Page 329, https://doi.org/10.1093/jnci/34.2.329 Published: 01 February 1965
Book Review The Changing Economics of Medical Technology (Medical Innovation at the Crossroads. Vol. 2.) Edited by Annetine C. Gelijns and Ethan A. Halm. 210 pp. Washington, D.C., National Academy Press, 1992. $24.95. 0-309-04491-X Technology and Health Care in an Era of Limits (Medical Innovation at the Crossroads. Vol. 3.) Edited by Annetine C. Gelijns. 283 pp. Washington, D.C., National Academy Press, 1992. $36. 0-309-04695-5
Authors: Seymour Perry
Journal: New England Journal of Medicine (1993)
Infectious Diseases
Journal: JAMA (2000)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Bernhard Bang, (1848-1932) veterinary physician
Journal: JAMA (1969)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Latent tuberculosis screening and treatment among asylum seekers: a mixed-methods study
Authors: Ineke Spruijt, Connie Erkens, Susan van den Hof, Frank Cobelens
Journal: European Respiratory Journal (2020)

<b>Europe-wide collaboration for the identification and treatment of latent tuberculosis infection is important to further address and prevent tuberculosis among high-risk asylum seekers. To achieve this, existing barriers need to be addressed.</b>https://bit.ly/2JoFiqx
TUMORS OF THE CAROTID GLAND.
Journal: JAMA (1905)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal